Your Global Leader in Stem Cell Market Research
Overland Park, KS – Ronawk, a trailblazing biotechnology company committed to advancing next-generation therapies through innovation powered by Roanwk’s Bio-Block™ platform, is delighted to announce that its CEO and Co-Founder, Dr.
A.J. Mellott, has been elected to serve as a Director on the esteemed Board of Directors of the Biomedical Engineering Society (BMES). [Read more…]
Paris, France – iPSirius today announced its decision to focus on advanced non-small cell lung cancer as the first indication for its comprehensive stem cell-based immunotherapy in the inaugural first-in-human clinical trial. Furthermore, the company declared its intention to apply for a clinical trial  licence and undertake the clinical trial in the United Kingdom, to leverage the integrated clinical infrastructure, there, as well as take advantage of the country’s extensive biotech expertise and the UK government’s commitment to innovative healthcare solutions. [Read more…]
In major news that broke this morning, Celularity (CELU) has announced a partnership with Regeneron (REGN) to support the research, preclinical development, and manufacturing of allogeneic targeted cell therapy candidates targeting difficult-to-treat cancers.
The selection follows months of rigorous assessment and due diligence by Regeneron and showcases a high level of confidence and validation of Celularity’s core science, business model, and strategic vision. Celularity’s expertise in the off-the-shelf allogeneic cell therapy field is exceptional and includes the engineering and design of chimeric antigen receptors (CAR) for use with T and natural Killer (NK) cells. [Read more…]
TOKYO and KANAGAWA, JAPAN –  PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-derived regenerative medicine have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of regenerative medicine product developed by OZTx. [Read more…]
NEW YORK, NY – Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company’s strides in dealing with infectious disease and sepsis with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death. This is in addition to the Company’s combatting traumatic brain injuries and other neuronal diseases. [Read more…]
